Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03567720
Title Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncoSec Medical Incorporated
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab + Tavokinogene telseplasmid

Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.